KOL Insight: Hepatitis C: the Race for the First Interferon-free Regimen Analyzing the Hepatitis C Market Landscape After more than a decade of limited treatment options, the hepatitis C (HCV) market is on the cusp of a treatment revolution. In 2011, protease inhibitors-Incivek (telaprevir; Vertex) and Victrelis (boceprevir; ...
Therapy Trends Consensus Outlook: Hepatitis C The worldwide hepatitis C (HCV) market is forecast to grow from $3.8 billion in 2011 to $14.5 billion in 2020. The catalysts for this growth include a boost in diagnosis rates following an increase in screening, and the introduction more effective and ...
Hepatitis C (HCV) Market Forecast & Drugs Pipeline Analysis to 2016 Hepatitis C virus drug market is experiencing a dramatic near-term growth, by crossing US$ 6 Billion in 2011 and is expected to be more than double of its current figure by 2015. This robust growth will be driven primarily by the launch of novel premium- ...